- Home
- SLN vs AMRC Comparison
SLN vs AMRC Comparison
Compare SLN & AMRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLN | AMRC |
|---|---|---|
| Founded | 1994 | 2000 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Engineering & Construction |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2010 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SLN | AMRC |
|---|---|---|
| Price | $19.76 | $22.65 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 12 |
| Target Price | $19.75 | ★ $41.40 |
| AVG Volume (30 Days) | ★ 4.4M | 574.8K |
| Earning Date | 11-20-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $559,000.00 | ★ $1,769,928,000.00 |
| Revenue This Year | N/A | $10.38 |
| Revenue Next Year | $131.31 | $8.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.19 | $18.09 |
| 52 Week High | $19.87 | $37.14 |
Technical Indicators
Market Signals| Indicator | SLN | AMRC |
|---|---|---|
| Relative Strength Index (RSI) | 78.21 | 56.94 |
| Support Level | $13.01 | $21.00 |
| Resistance Level | $19.87 | $23.87 |
| Average True Range (ATR) | 0.07 | 1.48 |
| MACD | -0.04 | 0.34 |
| Stochastic Oscillator | 58.49 | 78.20 |
Price Performance
Historical ComparisonAbout SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About AMRC Ameresco Inc.
Ameresco Inc is an energy infrastructure solutions provider dedicated to helping customers reduce costs, enhance resilience, and decarbonize to net zero in the energy transition. Its comprehensive portfolio includes implementing smart energy efficiency solutions, upgrading aging infrastructure, and developing, constructing, and operating distributed energy resources. Its solutions range from upgrades to facility's energy infrastructure to the development, construction and operation of renewable energy plants combined with tailored financial solutions. Its segments include North America Regions, U.S. Federal, Renewable Fuels, Europe, and Others. The majority of the revenue is derived from North America Regions segment.